Search Result

Pathways Recommended:	TGF-beta/Smad

Results for "

Beta Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) 17β-HSD (4) Amyloid-β (20) TGF-beta/Smad (19) TGF-β Receptor (39) β-catenin (6) 5-HT Receptor (36) Adenosine Receptor (1) Adiponectin Receptor (2) Adrenergic Receptor (334) Akt (8) Aldose Reductase (1) Aminopeptidase (1) AMPK (3) Amylin Receptor (1) Anaplastic lymphoma kinase (ALK) (3) Androgen Receptor (9) Angiotensin Receptor (4) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (12) Antifolate (1) AP-1 (1) Apelin Receptor (APJ) (8) Apoptosis (62) Arrestin (20) Aryl Hydrocarbon Receptor (3) ATM/ATR (1) Autophagy (71) AUTOTACs (1) Bacterial (25) Bcl-2 Family (1) Bcr-Abl (1) Biochemical Assay Reagents (7) Bradykinin Receptor (1) c-Fms (1) c-Kit (13) c-Met/HGFR (4) C-type Lectin-like Receptors (CTLRs) (1) Calcium Channel (25) Cannabinoid Receptor (17) Caspase (2) CD28 (1) CD3 (1) CDK (2) CFTR (1) CGRP Receptor (4) Chemerin Receptor (2) Chloride Channel (2) Cholecystokinin Receptor (2) Cholinesterase (ChE) (8) Collagen (1) COX (1) CRFR (7) CXCR (5) Cytochrome P450 (5) DAGL (1) Dengue Virus (2) DNA/RNA Synthesis (8) Dopamine Receptor (13) Dopamine Transporter (2) Drug Intermediate (2) Drug Isomer (1) Drug Metabolite (13) E3 Ligase Ligand-Linker Conjugates (2) EGFR (4) Endogenous Metabolite (82) Ephrin Receptor (3) Epigenetic Reader Domain (1) ERK (9) Estrogen Receptor/ERR (98) FAAH (1) Fatty Acid Synthase (FASN) (1) Ferroptosis (1) FGFR (14) Flavivirus (2) FLT3 (4) Fluorescent Dye (3) Formyl Peptide Receptor (FPR) (3) Free Fatty Acid Receptor (4) Fungal (9) FXR (7) GABA Receptor (61) GCGR (2) GLP Receptor (1) Glucocorticoid Receptor (6) GLUT (2) Glycosidase (2) GnRH Receptor (2) GPR119 (1) GSK-3 (2) HBV (1) HCV (1) HDAC (1) HIF/HIF Prolyl-Hydroxylase (5) Histamine Receptor (8) HIV (3) HSV (3) Hydroxycarboxylic Acid Receptor (HCAR) (1) IFNAR (3) iGluR (11) IKK (5) Imidazoline Receptor (5) Influenza Virus (1) Insecticide (3) Insulin Receptor (4) Integrin (15) Interleukin Related (21) IRAK (1) IRE1 (6) Isotope-Labeled Compounds (85) JAK (1) Keap1-Nrf2 (6) LDLR (1) Leukotriene Receptor (2) LPL Receptor (2) LXR (15) mAChR (24) MAP3K (1) Mas-related G-protein-coupled Receptor (MRGPR) (2) MDM-2/p53 (1) Melanocortin Receptor (4) Melatonin Receptor (1) mGluR (2) Mitochondrial Metabolism (1) Mitophagy (15) MMP (1) MNK (1) Molecular Glues (1) Monoamine Oxidase (4) MyD88 (1) nAChR (78) NADPH Oxidase (2) Necroptosis (3) Neurokinin Receptor (2) Neuropeptide Y Receptor (2) Neurotensin Receptor (2) NF-κB (13) NO Synthase (3) NOD-like Receptor (NLR) (1) Nucleoside Antimetabolite/Analog (3) Opioid Receptor (21) Organoid (6) Orphan Receptor (1) Oxytocin Receptor (2) P2X Receptor (12) P2Y Receptor (7) p38 MAPK (7) Parasite (10) PD-1/PD-L1 (2) PDGFR (39) Peptide-Drug Conjugates (PDCs) (1) PERK (1) PGC-1α (2) Phosphatase (4) Phosphodiesterase (PDE) (5) PI3K (3) PKA (2) PKC (2) Platelet-activating Factor Receptor (PAFR) (2) Potassium Channel (12) PPAR (17) Progesterone Receptor (2) Prostaglandin Receptor (10) PROTACs (2) Protease Activated Receptor (PAR) (2) PTHR (3) Radionuclide-Drug Conjugates (RDCs) (1) Raf (6) RAR/RXR (27) Ras (1) Reactive Oxygen Species (10) Reference Standards (15) Renin (3) RET (7) Reverse Transcriptase (2) ROCK (1) ROR (1) ROS Kinase (1) SARS-CoV (2) Serpin (1) Sigma Receptor (2) Sirtuin (5) Small Interfering RNA (siRNA) (2) Sodium Channel (17) Somatostatin Receptor (1) Src (7) STAT (3) Stearoyl-CoA Desaturase (SCD) (1) STING (2) Survivin (1) Tau Protein (2) Thyroid Hormone Receptor (38) Tie (5) TNF Receptor (13) Toll-like Receptor (TLR) (9) TRP Channel (11) TSH Receptor (1) VD/VDR (2) VEGFR (34) Virus Protease (1) Wnt (13) α-synuclein (2)
By Research Areas:	Cancer (338) Cardiovascular Disease (274) Endocrinology (211) Infection (52) Inflammation/Immunology (210) Metabolic Disease (126) Neurological Disease (316)
Click Chemistry:	Alkynes (3)
Oligonucleotides:	Nucleosides and their Analogs (2) Aptamers (1) CpG ODNs (2) siRNA drugs (2) siRNAs (2)

1109

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

117

Natural
Products

155

Recombinant Proteins

123

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Amyloid-β TGF-β Receptor Beta-secretase β-glucuronidase TGF-beta/Smad 17β-HSD β-catenin 11β-HSD Beta-lactamase Dopamine β-hydroxylase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150693

*Estrogen receptor* β antagonist 2**	Estrogen Receptor/ERR	Cancer
Estrogen receptor β antagonist 2 is a potent and selective *estrogen receptor* β (ERβ) antagonist with IC₅₀**s of 109.10, 0.63 µM for Erα and Erβ, respectively .

HY-12452

DPN 10+ Cited Publications Diarylpropionitrile	Estrogen Receptor/ERR Apoptosis Autophagy	Neurological Disease
DPN (Diarylpropionitrile) is a non-steroidal *estrogen receptor* β (ERβ) selective ligand, with an EC₅₀** of 0.85 nM. DPN has neuroprotective effects in a number of neurological diseases .

HY-B0203A

Nebivolol hydrochloride 3 Publications Verification R 065824 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Nebivolol (R 065824) hydrochloride is an orally active **beta receptor** blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-B0203

Nebivolol 3 Publications Verification R 065824	Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Nebivolol (R 065824) is an orally active **beta receptor** blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-148526

*β2AR/M3-receptor* agonist-1**	Adrenergic Receptor mAChR	Metabolic Disease
β2AR/M3-receptor agonist-1 (example 9) is a potent *β2AR* and M3 receptor agonist. β2AR/M3-receptor agonist-1 shows M3 receptor affinity with a pIC₅₀ value of 9.3. β2AR/M3-receptor agonist-1 has the potential for the research of respiratory tract disorders .

HY-153477

*Thyroid hormone receptor* beta agonist-1**	Thyroid Hormone Receptor	Cancer
Thyroid hormone receptor beta agonist-1 (compound 3) is a thyroid beta-agonist .

HY-148524

*β2AR/M-receptor* agonist-1**	mAChR Adrenergic Receptor	Cardiovascular Disease
β2AR/M-receptor agonist-1 (example 131) is a muscarinic antagonist and β2 adrenoceptor agonist (MABA). β2AR/M-receptor agonist-1 shows potency to β2 adrenoceptor with an EC₅₀ value of 9.2 nM. β2AR/M-receptor agonist-1 also has potency to muscarinic receptor with a K_i value of 30.2 nM. β2AR/M-receptor agonist-1 shows MABA potency with an EC₅₀ value of 4.0 nM .

HY-148525

PF-4348235 β2AR/M-Receptor agonist-2	mAChR Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology
β2AR/M-receptor agonist-2 (compound 15) is a muscarinic antagonist and β2 adrenoceptor agonist (MABA). β2AR/M-receptor agonist-2 shows potency to β2 adrenoceptor with an EC₅₀ value of 3.7 nM. β2AR/M-receptor agonist-2 also has potency to human cloned M3 receptor with a K_i value of 0.73 nM. β2AR/M-receptor agonist-2 is a potent bronchodilator, it can be used for the research of chronic obstructive pulmonary disease (COPD) .

HY-D2280

*Estrogen receptor* β/HDAC probe 1**	HDAC Estrogen Receptor/ERR	Others
Estrogen receptor β/HDAC probe 1 (compound P1) is a near-infrared fluorescent probe that dual-targets the estrogen receptor (Estrogen Receptor/ERR) β/histone deacetylase HDAC .

HY-148533

*β2AR agonist /M-receptor* antagonist-1**	mAChR Adrenergic Receptor	Neurological Disease
β2AR agonist /M-receptor antagonist-1 is a potent dual *muscarinic antagonist/beta* 2 agonist (MABA)*. β2AR agonist /M-receptor* antagonist-1 potently relaxes either Carbachol (HY-B1208)-induced contraction, in the absence (MABA) or presence of Propranolol (M3; HY-B1208), or Histamine (HY-B1204)-induced contraction (β2) .

HY-160053

Gint4.T aptamer sodium	PDGFR	Cancer
Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .

HY-B0432

Propafenone 1 Publications Verification SA-79	Sodium Channel Adrenergic Receptor Potassium Channel	Cardiovascular Disease Cancer
Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC₅₀=32 nM) . Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC₅₀ values of 4.9 μm and 8.6 μm, respectively . Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis .

HY-B0432R

Propafenone (Standard)	Sodium Channel Adrenergic Receptor Potassium Channel	Cardiovascular Disease Cancer
Propafenone (Standard) is the analytical standard of Propafenone. This product is intended for research and analytical applications. Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC₅₀=32 nM) . Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC₅₀ values of 4.9 μm and 8.6 μm, respectively . Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis .

HY-153535

THRβ receptor agonist-1	Thyroid Hormone Receptor	Metabolic Disease
THRβ receptor agonist-1 is a THRβ receptor agonist .

HY-151230

(-)-Erteberel	Estrogen Receptor/ERR	Cancer
(-)-Erteberel is a selective estrogen receptor beta (ERβ) agonist. (-)-Erteberel can be utilized in the study of diseases mediated by estrogen receptor beta (ERβ), such as prostate cancer .

HY-123012

Lubabegron LY-488756	Adrenergic Receptor	Others
Lubabegron is a potent modulator of β-adrenergic receptor (β -AR). Lubabegron demonstrates antagonistic behavior at the β₁ and β ₂ receptor subtypes and agonistic behavior at the β ₃ receptor subtype in cattle. Lubabegron reduces NH₃ gas emissions from an animal or its waste .

HY-13713

LY377604	Adrenergic Receptor	Metabolic Disease Endocrinology
LY377604 is a human β₃-adrenergic receptor agonist with an EC₅₀ of 2.4 nM and also a β₁- and β₂-adrenergic *receptor* antagonist.

HY-P99171

Gevokizumab	Interleukin Related	Inflammation/Immunology Cancer
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates *IL-1β* signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of *IL-1β* for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) .

HY-129029

Bisoprolol 5+ Cited Publications	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

HY-120829

Bisoprolol fumarate	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Bisoprolol fumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol fumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

HY-B0436

Salbutamol hemisulfate 4 Publications Verification Albuterol hemisulfate; AH-3365 hemisulfate	Adrenergic Receptor Autophagy	Inflammation/Immunology Endocrinology Cancer
Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting β2 adrenergic receptor agonist Target: β2 Adrenergic Receptor Salbutamol Hemisulfate (Albuterol hemisulfate) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD.

HY-B0076

Bisoprolol hemifumarate 5+ Cited Publications	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Bisoprolol hemifumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol hemifumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

HY-13951

Zenidolol hydrochloride 35+ Cited Publications ICI-118551 hydrochloride	Adrenergic Receptor	Neurological Disease Endocrinology
Zenidolol (ICI-118551) hydrochloride is a highly selective β2 adrenergic receptor antagonist, with K_is of 0.7, 49.5 and 611 nM for β2, β1 and β3 receptors, respectively.

HY-125787

MLS000389544	Thyroid Hormone Receptor	Metabolic Disease
MLS000389544 is a selective and potent methylsulfonylnitrobenzoate thyroid hormone receptor β (TRβ) antagonist that blocks the association of TRβ with steroid receptor coactivator 2 (SRC2) .

HY-105272A

Loreclezole hydrochloride R 72063 hydrochloride	GABA Receptor	Neurological Disease
Loreclezole hydrochloride, an antiepileptic compound, is a selective GABA_A receptor modulator and acts as a positive allosteric modulator of β2 or β3-subunit containing receptors .

HY-105272

Loreclezole R 72063	GABA Receptor	Neurological Disease
Loreclezole, an antiepileptic compound, is a selective GABA_A receptor modulator and acts as a positive allosteric modulator of β2 or β3-subunit containing receptors .

HY-117239

SB-206606	Adrenergic Receptor	Cardiovascular Disease
SB-206606, a stereoisomer of BRL 37344, is a potentially specific, beta 3-adrenergic receptor (β₃-AR) ligand. The affinity of [3H]SB 206606 is 76 times higher for the β₃-AR than for the beta 1/beta 2-adrenergic receptors .

HY-103200

SR59230A hydrochloride 10+ Cited Publications	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease
SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC₅₀s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively .

HY-100672

SR59230A 10+ Cited Publications	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease
SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC₅₀s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively .

HY-W707407

Bisoprolol-d7	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Bisoprolol-d₇ is deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

HY-B1270A

Isoxsuprine	Adrenergic Receptor iGluR	Neurological Disease Endocrinology
Isoxsuprine is a **beta-adrenergic receptor agonist with K_i*s of 13.65 μΜ and 3.48 μΜ for myometrial and placcntal beta-adrenergic receptor, respectively. Isoxsuprine hydrochloride is also a NMDA receptor* antagonist.

HY-B1270

Isoxsuprine hydrochloride	Adrenergic Receptor iGluR	Neurological Disease Endocrinology
Isoxsuprine hydrochloride is a **beta-adrenergic receptor agonist with K_i*s of 13.65 μΜ and 3.48 μΜ for myometrial and placcntal beta-adrenergic receptor, respectively. Isoxsuprine hydrochloride is also a NMDA receptor* antagonist.

HY-13338S

Mabuterol-d9	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology
Mabuterol-d₉ is a deuterium labeled Mabuterol. Mabuterol is an agonist of the β2-adrenergic receptor[1].

HY-153637

THR-β modulator-1	Thyroid Hormone Receptor	Endocrinology
THR-β modulator-1 (compound 1a) is a potent *thyroid hormone receptor* β** modulator. THR-β modulator-1 can be used in research of thyroid hormone receptor related disorders .

HY-P1502F

Biocytin-β-endorphin, human	Opioid Receptor	Neurological Disease
Biocytin-β-endorphin, human is abiotinylated β-Endorphin, human (HY-P1502). β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioid receptor, with preferred affinity for μ-opioid receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.

HY-129029S

Bisoprolol-d5	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease
Bisoprolol-d₅ is the deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research[1][2].

HY-160416

THR-β modulator-2	Thyroid Hormone Receptor	Endocrinology
THR-β modulator-2 (compound 40) is a thyroid hormone receptor β (THR-β) modulator .

HY-129029R

Bisoprolol (Standard)	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Bisoprolol (Standard) is the analytical standard of Bisoprolol. This product is intended for research and analytical applications. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

HY-158186S

Bisoprolol-d6 hemifumarate	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Bisoprolol-d₆ fumarate is deuterium labeled Bisoprolol (hemifumarate). Bisoprolol hemifumarate is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol hemifumarate has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

HY-124463

Epiallopregnanolone 5α,3β-THDOC	GABA Receptor iGluR	Neurological Disease
Epiallopregnanolone (5α,3β-THDOC), a 3β-hydroxy neurosteroid, an antagonist at GABAA receptors and a NMDA receptor enhancer .

HY-19468

ERB-196 WAY-202196	Estrogen Receptor/ERR	Neurological Disease Inflammation/Immunology
ERB-196 is a nonsteroidal selective estrogen receptor-β (ERβ) agonist.

HY-141468

β-Chlornaltrexamine dihydrochloride β-CNA dihydrochloride	Opioid Receptor	Neurological Disease
β-Chlornaltrexamine dihydrochloride (β-CNA dihydrochloride) is a potent long-term opioid receptor blocker. β-Chlornaltrexamine dihydrochloride can effectively block the inhibitory effect of κ opioid receptor agonists on dopamine release. β-Chlornaltrexamine dihydrochloride can be used to study the mechanism of pain perception .

HY-120188

CC618	PPAR	Others
CC618 is a selective peroxisome proliferator-activated receptor (PPARβ/δ) antagonist that exhibits antagonism by covalently binding to PPARβ/δ receptors .

HY-148804

Vemtoberant APD418	Adrenergic Receptor	Endocrinology
Vemtoberant is an β₃ Adrenergic Receptor antagonist. Vemtoberant can be used for research of β₃ adrenergic receptor-mediated disorder, such as, heart failure .

HY-148804A

Vemtoberant mesylate APD418 mesylate	Adrenergic Receptor	Endocrinology
Vemtoberant mesylate is an β₃ Adrenergic Receptor antagonist. Vemtoberant mesylate can be used for research of β₃ adrenergic receptor-mediated disorder, such as, heart failure .

HY-139727A

S(-)-Bisoprolol fumarate	Adrenergic Receptor	Cardiovascular Disease
S(-)-Bisoprolol fumarate is a S(-)-enantiomer of Bisoprolol fumarate. Bisoprolol fumarate is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

HY-139727

S(-)-Bisoprolol	Adrenergic Receptor	Cardiovascular Disease
S(-)-Bisoprolol is a S(-)-enantiomer of Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

HY-B0381B

Levobetaxolol hydrochloride (S)-Betaxolol hydrochloride; AL-1577A	Adrenergic Receptor	Cardiovascular Disease Neurological Disease Endocrinology
Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker) that can lower the pressure in the eye.

HY-19012

N-1518	Adrenergic Receptor	Cardiovascular Disease
N-1518 is an α and β adrenergic receptor blocker that has competitive antagonism against β1 and α1 receptors, but does not show selectivity for β1 receptors, but shows about 20-fold selectivity for α1 receptors. N-1518 has vasodilatory effects and can be used in the research field of hypertension treatment .

HY-W722221

Colterol acetate	Adrenergic Receptor	Cardiovascular Disease
Colterol acetate is a selective inhibitor of β-adrenergic receptors. Colterol acetate can relax tracheal smooth muscle (primarily acting on β2 receptors), reduce subspastic contractions of tricholoma (acting on β2), and increase contractility of left ventricular papillary muscles (acting on β1) .

Cat. No.	Product Name

HY-L018

TGF-beta/Smad Compound Library

317 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 317 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

HY-L013

Neuronal Signaling Compound Library

3,216 compounds

Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.

MCE designs a unique collection of 3,216 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.

HY-L033

Peptidomimetic Library

374 compounds

Peptidomimetics are compounds whose essential elements (pharmacophore) mimic a natural peptide or protein in 3D space and which retain the ability to interact with the biological target and produce the same biological effect. Peptidomimetics are designed to circumvent some of the problems associated with a natural peptide: e.g. stability against proteolysis (duration of activity) and poor bioavailability. Certain other properties, such as receptor selectivity or potency, often can be substantially improved. The design and synthesis of peptidomimetics are most important because of the dominant position peptide and protein-protein interactions play in molecular recognition and signaling, especially in living systems. Hence mimics have great potential in drug discovery.

MCE Peptidomimetic Library contains 374 compounds including peptoid, α-helix mimetics, β-turn/sheets mimetics, etc. This library is an indispensable tool of structure-activity relationships in drug discovery.

HY-L086

Neurodegenerative Disease-related Compound Library

2,902 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2,902 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L069

Anti-Alzheimer's Disease Compound Library

1,694 compounds

Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc.

MCE offers a unique collection of 1,694 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

HY-L156

Autoimmune Disease Compound Library

656 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 656 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

HY-L145

Antihypertensive Compound Library

754 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 754 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

HY-L074

Anti-Breast Cancer Compound Library

2,484 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,484 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

HY-L040

Anti-diabetic Compound Library

876 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 876 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Type

HY-D1734

FITC-GW3965	Fluorescent Dyes/Probes
FITC-GW3965 is a fluorescence-labelled liver X receptor β (LXRβ) agonist GW3965 (HY-10627). FITC-GW3965 is a tracer, that can be designed by replacing the trifluoromethyl of GW3965 with an amide to link the FITC. FITC-GW3965 can be used to study the function of LXRβ .

HY-A0070AG

Liothyronine (GMP) Triiodothyronine (GMP); 3,3',5-Triiodo-L-thyronine (GMP); T3 (GMP)	Fluorescent Dye
Liothyronine (Triiodothyronine) (GMP) is the Liothyronine (HY-A0070A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with K_is of 2.33 nM for hTRα and hTRβ, respectively .

HY-10431G

SB-431542 (GMP)	Fluorescent Dye
SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a *TGF-β receptor* kinase inhibitor (TRKI)** in SMAD signaling .

HY-D0914

Fast Green FCF

FD&C Green No. 3; Food green 3; C.I. 42053

Dyes

Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

HY-D2280

*Estrogen receptor* β/HDAC probe 1**	Fluorescent Dyes/Probes
Estrogen receptor β/HDAC probe 1 (compound P1) is a near-infrared fluorescent probe that dual-targets the estrogen receptor (Estrogen Receptor/ERR) β/histone deacetylase HDAC .

HY-D2439

RGD-PEG-Cy3

Fluorescent Dyes/Probes

RGD-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, peptide (RGD) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. RGD is a peptide sequence (CRGDKGPDCiRGD) that binds to αvβ3 and αvβ5 integrin receptors on tumor neovasculogenesis to achieve specific tumor tissue targeting .

HY-10407G

SU 5402 (GMP)	Fluorescent Dye
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively .

HY-16561G

Resveratrol (GMP)

trans-Resveratrol (GMP); SRT501 (GMP)

Fluorescent Dye

Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-D0914A

Fast green FCF free acid

Dyes

Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .

Cat. No.	Product Name	Type

HY-139413

β-D-Glucan	Carbohydrates
β-D-glucan is a natural non-digestible polysaccharide and high biocompatibility that can be selectively recognized by recognition receptors such as Dectin-1 and Toll-like receptors as well as being easily internalized by murine or human macrophages, which is likely to attribute to a target delivery . β-d-glucan is an enteric delivery vehicle for probiotics .

HY-114364

UDP-Galactose disodium

Gene Sequencing and Synthesis

UDP-Galactose disodium is a natural agonist of the P2Y₁₄ receptor with an EC₅₀ of 0.67 μM for the hP2Y₁₄ receptor. UDP-Galactose disodium is a substrate for the transferase beta-1, 4 galactosyltransferase V (B4GALT5). In addition, UDP-Galactose disodium is required for the biosynthesis of several abundant glycoconjugates that form the surface glycocalyx of Leishmania major .

HY-A0144A

Etilefrine hydrochloride	Biochemical Assay Reagents
Etilefrine hydrochloride, a sympathetic agent, is an α and β adrenergic receptors agonist . Etilefrine hydrochloride also is an AMPK activator . Etilefrine hydrochloride can be used for the research of postural hypotension and chylothorax .

HY-A0070AG

Liothyronine (GMP) Triiodothyronine (GMP); 3,3',5-Triiodo-L-thyronine (GMP); T3 (GMP)	Biochemical Assay Reagents
Liothyronine (Triiodothyronine) (GMP) is the Liothyronine (HY-A0070A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Liothyronine is a potent thyroid hormone receptors TRα and TRβ agonist with K_is of 2.33 nM for hTRα and hTRβ, respectively .

HY-40421

(R)-3-Fluoropyrrolidine hydrochloride	Biochemical Assay Reagents
(R)-3-Fluoropyrrolidine hydrochloride is a derivative of fluorinated pyrrolidines. The amide series of fluorinated pyrrolidines are inhibitors of dipeptidyl peptidase DP-IV. Novel α4β2 receptor ligands characterized by a 3-Fluoropyrrolidine core .

HY-W145662

Octadecylthioethyl 4-O-α-D-galactopyranosyl-β-D-galactopyranoside	Carbohydrates
Octadecylthioethyl 4-O-α-D-galactopyranosyl-β-D-galactopyranoside is a glycolipid receptor that can be used to study lipid regulation mechanisms .

HY-W127641R

β-Methylcholine chloride (Standard)

Biochemical Assay Reagents

β-Methylcholine (chloride) (Standard) is the analytical standard of β-Methylcholine (chloride). This product is intended for research and analytical applications. β-Methylcholine chloride is an organic compound containing choline and chloride ions. It is commonly used as a pharmacological research tool, especially in the study of acetylcholine receptors and signaling pathways. β-Methylcholine chloride has various applications in the pharmaceutical industry, especially as a standard reference material for the calibration of analytical instruments. In addition, it can be used in the production of other choline derivatives and as a precursor of neurotransmitters.

HY-120973

Butaprost free acid	Biochemical Assay Reagents
Butaprost free acid is a selective *prostaglandin E receptor* (EP2) agonist with an EC₅₀ of 33 nM and a K_i** of 2.4 μM for murine EP2 receptor. Butaprost free acid is less activity against murine EP1, EP3 and EP4 receptors. Butaprost free acid attenuates fibrosis by hampering *TGF-β/Smad2* signalling .

HY-W698686

β-Galactosyl-C18-ceramide

Cell Assay Reagents

β-Galactosyl-C18-ceramide is a bioactive molecule that promotes the regulation of nerve cells, regulates protein kinase C activity, and affects hormone receptors. β-Galactosyl-C18-ceramide is widely used in neuroscience research to explore its effects on nerve cell growth and function. The regulatory function of β-Galactosyl-C18-ceramide makes it a potential application prospect in compound development and disease inhibition.

HY-A0144AR

Etilefrine (hydrochloride) (Standard)

Biochemical Assay Reagents

Etilefrine hydrochloride (Standard) is the analytical standard of Etilefrine hydrochloride (HY-A0144A). This product is intended for research and analytical applications.Etilefrine hydrochloride, a sympathetic agent, is an α and β adrenergic receptors agonist. Etilefrine hydrochloride also is an AMPK activator. Etilefrine hydrochloride can be used for the research of postural hypotension and chylothorax.

HY-10431G

SB-431542 (GMP)	Biochemical Assay Reagents
SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a *TGF-β receptor* kinase inhibitor (TRKI)** in SMAD signaling .

HY-10407G

SU 5402 (GMP)	Biochemical Assay Reagents
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively .

HY-16561G

Resveratrol (GMP)

trans-Resveratrol (GMP); SRT501 (GMP)

Biochemical Assay Reagents

HY-P2975

Laminin β2 (Engelbreth-Holm-Swarm murine sarcoma basement membrane)

Mouse laminin (Engelbreth-Holm-Swarm murine sarcoma basement membrane)

Native Proteins

Laminin β2 (Engelbreth-Holm-Swarm murine sarcoma basement membrane) is a crucial structural element in animal tissues, forming part of the scaffolding that supports tissue architecture. It interacts with type IV collagen through entactin and perlecan, connects to cell membranes via integrin receptors, dystroglycan complexes, and Lutheran blood group glycoproteins, and contains functional domains that facilitate collagen binding, cell adhesion, heparin interaction, and promote neurite outgrowth.

Cat. No.	Product Name	Target	Research Area

HY-P99171

Gevokizumab	Interleukin Related	Inflammation/Immunology Cancer
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates *IL-1β* signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of *IL-1β* for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II) .

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .

HY-P99222

Teplizumab MGA-031; PRV-031	CD3	Metabolic Disease
Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes .

HY-P99333

Volociximab 1 Publications Verification M200; Eos 200-4	Integrin	Cardiovascular Disease Cancer
Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC₅₀=0.2 nM). Integrin α5β1 is a major fibronectin receptor involved in angiogenesis. Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs) .

HY-P99519

Vixarelimab 1 Publications Verification KPL-716	Interleukin Related	Inflammation/Immunology
Vixarelimab (KPL-716) is a human *anti-oncostatin M (OSM) receptor* β subunit monoclonal antibody. Vixarelimab inhibits IL-31** and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash .

HY-P99614

Fazpilodemab BFKB8488A; RG-7992; RO-7040551	FGFR	Metabolic Disease
Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD) .

HY-P990958

Invikafusp alfa	Inhibitory Antibodies	Inflammation/Immunology
HY-P990958 is an *T cell receptor* germline-encoded variable chain Vβ6/β10**-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991084

TQB-2858	PD-1/PD-L1	Cancer
TQB-2858 is a bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of TGF-β receptor. TQB-2858 has a high affinity for PD-L1, TGF-β1, and TGF-β3 and exhibited high PD-L1 target occupancy. TQB-2858 can be used for the study of osteosarcoma and alveolar soft part sarcoma (ASPS) .

HY-P990720

Elritercept KER-050	TGF-beta/Smad	Inflammation/Immunology
Elritercept (KER-050) is a recombinant fusion protein comprising a modified activin receptor type IIA extracellular domain fused to a human IgG1 Fc. Elritercept inhibits activin A and other select TGF-β superfamily ligands .

HY-P99963

Sudubrilimab HS636	PD-1/PD-L1	Cancer
Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody against PDL1. Sudubrilimab is fused at the C terminus of the heavy chain to a TGF-β1 receptor Ⅱ ectodomain (TGFBR2-ECD), and which can sequester the PD-1/PD-L1 pathway and TGF-β bioactivity in the immunosuppressive tumor microenvironment .

HY-108847

Etanercept Maximum Cited Publications 8 Publications Verification	TNF Receptor Bacterial	Inflammation/Immunology Cancer
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis .

HY-P99459

Baminercept BG 9924; TT-47	TNF Receptor	Inflammation/Immunology
Baminercept (BG 9924) is an *anti-lymphotoxin β receptor* (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT**, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .

HY-P99410

Ordesekimab AMG 714; PRV-015	Interleukin Related	Inflammation/Immunology
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD) .

Beta Receptor

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products